Novartis Sees Profit Gaining Despite Copycats for Top Drug
Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...
Swissinfo7h
Novartis to Buy Anthos Therapeutics for Up to $3.1 Billion
Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind.
PharmaTimes6d
Novartis secures MHRA authorisation for ribociclib
Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...
pharmaphorum9d
Novartis decides Sandoz' future – and it's a spin-out
Novartis started a review of the business in ... Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's ...
Seeking Alpha28d
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure.
Novartis Forecasts Profit Gains Despite Copycat Competition
( MENAFN - Swissinfo) Swiss Pharmaceutical heavyweight Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit ...